{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:25:26Z","timestamp":1786958726125,"version":"build-2736575974"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T00:00:00Z","timestamp":1786924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Pretreatment inflammatory indices may reflect the host immune-inflammatory status in breast cancer. Evidence comparing multiple composite indices across pathological response endpoints after neoadjuvant therapy remains limited. This study evaluated the associations between pretreatment composite inflammatory indices and pathological response in breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included 280 patients with breast cancer who underwent neoadjuvant therapy followed by surgery. Baseline neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammation index, systemic inflammation response index, and pan-immune-inflammation value were calculated from pretreatment blood tests. The primary endpoint was pathological complete response, defined as ypT0\/is ypN0. Miller-Payne grades 4\u20135 were defined as favorable pathological response. Logistic regression and receiver operating characteristic analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 115 patients achieved pathological complete response. Patients with pathological complete response had lower neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, and pan-immune-inflammation value than those without pathological complete response. These indices remained inversely associated with pathological complete response after multivariable adjustment. For favorable Miller-Payne response, lower systemic immune-inflammation index and pan-immune-inflammation value and higher lymphocyte-to-monocyte ratio were associated with better response. Systemic immune-inflammation index had the numerically highest area under the curve, with values of 0.673 for pathological complete response and 0.666 for favorable Miller\u2013Payne response, although its discriminatory ability remained modest.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Baseline composite inflammatory indices were associated with pathological response to neoadjuvant therapy in breast cancer, but their discriminatory ability was modest. These indices may be more suitable as supplementary markers than as standalone predictors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1913071","type":"journal-article","created":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:38:41Z","timestamp":1786955921000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Associations between pretreatment composite inflammatory indices and pathological response to neoadjuvant therapy in breast cancer: a retrospective cohort study"],"prefix":"10.3389","volume":"16","author":[{"given":"Yuhong","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cailing","family":"Tong","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, The First Affiliated Hospital of Guangzhou University of Chinese Medicine","place":["Guangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s10552-026-02138-z","article-title":"Breast cancer inequities: the intersectional role of social epidemiology and tumor biology","volume":"37","author":"Peiris","year":"2026","journal-title":"Cancer Causes Control"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyz213","article-title":"Adjuvant and neoadjuvant therapy for breast cancer","volume":"50","author":"Shien","year":"2020","journal-title":"Jpn J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.10.6823","article-title":"Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy","volume":"25","author":"Symmans","year":"2007","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/s0960-9776(03)00106-1","article-title":"A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival","volume":"12","author":"Ogston","year":"2003","journal-title":"Breast"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104389","article-title":"A review concerning the breast cancer-related tumour microenvironment","volume":"199","author":"Rodr\u00edguez-Bejarano","year":"2024","journal-title":"Crit Rev Oncol Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.09.007","article-title":"Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer","volume":"36","author":"Burstein","year":"2025","journal-title":"Ann Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02864","article-title":"Human epidermal growth factor receptor 2 testing in breast cancer: ASCO-college of American pathologists guideline update","volume":"41","author":"Wolff","year":"2023","journal-title":"J Clin Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znae132","article-title":"Predictive value of pretreatment circulating inflammatory response markers in the neoadjuvant treatment of breast cancer: meta-analysis","volume":"111","author":"Dowling","year":"2024","journal-title":"Br J Surg"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1177\/17588359231193732","article-title":"Low neutrophil-to-lymphocyte ratio and pan-immune-inflammation-value predict nodal pathologic complete response in 1274 breast cancer patients treated with neoadjuvant chemotherapy: a multicenter analysis","volume":"15","author":"Gasparri","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1658571","article-title":"Prognostic value of platelet to lymphocyte ratio (PLR) in breast cancer patients receiving neoadjuvant therapy: a systematic review and meta-analysis","volume":"16","author":"Zhao","year":"2025","journal-title":"Front Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1437140","article-title":"The role of systemic immune-inflammation index in predicting pathological complete response of breast cancer after neoadjuvant therapy and the establishment of related predictive model","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Oncol"},{"key":"B14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","article-title":"Inflammation and cancer: triggers, mechanisms, and consequences","volume":"51","author":"Greten","year":"2019","journal-title":"Immunity"},{"key":"B15","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","article-title":"Inflammation and tumor progression: signaling pathways and targeted intervention","volume":"6","author":"Zhao","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.clbc.2020.05.008","article-title":"Can the neutrophil to lymphocyte ratio predict complete pathologic response to neoadjuvant breast cancer treatment? A systematic review and meta-analysis","volume":"20","author":"Cullinane","year":"2020","journal-title":"Clin Breast Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"14662","DOI":"10.1038\/s41598-021-94184-7","article-title":"Low pan-immune-inflammation-value predicts better chemotherapy response and survival in breast cancer patients treated with neoadjuvant chemotherapy","volume":"11","author":"\u015eahin","year":"2021","journal-title":"Sci Rep"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1349021","article-title":"Association of immune inflammatory biomarkers with pathological complete response and clinical prognosis in young breast cancer patients undergoing neoadjuvant chemotherapy","volume":"14","author":"Li","year":"2024","journal-title":"Front Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s12943-025-02243-8","article-title":"Inflammation in cancer: therapeutic opportunities from new insights","volume":"24","author":"Xie","year":"2025","journal-title":"Mol Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1186\/s12967-024-05126-6","article-title":"The interaction of platelet-related factors with tumor cells promotes tumor metastasis","volume":"22","author":"Xue","year":"2024","journal-title":"J Transl Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01216-z","article-title":"Macrophage diversity in cancer dissemination and metastasis","volume":"21","author":"Mantovani","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2022.101355","article-title":"Correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer","volume":"18","author":"Meng","year":"2022","journal-title":"Transl Oncol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1186\/s12885-018-5051-9","article-title":"Predictive value of lymphocyte-to-monocyte ratio in the preoperative setting for progression of patients with breast cancer","volume":"18","author":"Goto","year":"2018","journal-title":"BMC Cancer"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.11.016","article-title":"Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"35","author":"Loibl","year":"2024","journal-title":"Ann Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00589-1","article-title":"Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1186\/s12885-015-2005-3","article-title":"Neutrophil\/Lymphocyte ratio has no predictive or prognostic value in breast cancer patients undergoing preoperative systemic therapy","volume":"15","author":"Suppan","year":"2015","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1913071\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T08:38:42Z","timestamp":1786955922000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1913071\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,17]]},"references-count":26,"alternative-id":["10.3389\/fonc.2026.1913071"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1913071","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,17]]},"article-number":"1913071"}}